



### CDC Institutional Biosafety Committee (IBC) Meeting Minutes

Date: August 15, 2025  
Time: 10:30 AM – 12:00 PM  
Location: MS Teams meeting

Member	Attendance	Member	Attendance
1. NCEZID/DVBD1	<input type="checkbox"/>	13. OLSR/DCLSR2	<input type="checkbox"/>
2. NCIRD/DVD	<input type="checkbox"/>	14. OLSR/OD4	<input checked="" type="checkbox"/>
3. NCEZID/DHCPP1	<input checked="" type="checkbox"/>	16. OLSR/DCLSR3	<input checked="" type="checkbox"/>
4. OLSR/OD1	<input checked="" type="checkbox"/>	17. NCEZID/OD	<input checked="" type="checkbox"/>
5. OCOO/OSSAM/OHC	<input type="checkbox"/>	18. OLSR/OD2	<input checked="" type="checkbox"/>
6. NCEZID/DVBD2	<input checked="" type="checkbox"/>	19. NCHHSTP/DHP2	<input type="checkbox"/>
7. OLSR/OD3	<input checked="" type="checkbox"/>	20. Outside Member/Atlanta1	<input checked="" type="checkbox"/>
8. NCEZID/OD2	<input checked="" type="checkbox"/>	21. Outside Member/Atlanta2	<input checked="" type="checkbox"/>
9. NCHHSTP/DTE	<input type="checkbox"/>	22. Outside Member/Fort Collins	<input checked="" type="checkbox"/>
10. NCIRD/ID	<input checked="" type="checkbox"/>	23. Outside Member/Puerto Rico	<input checked="" type="checkbox"/>
11. NCIRD/CORVD	<input checked="" type="checkbox"/>	24. GHC/OD	<input checked="" type="checkbox"/>
12. OLSR/DCLSR1	<input checked="" type="checkbox"/>	Visitor(s)	4

#### Agenda

1. Welcome from the Chair
2. Review and approval of July 24, 2025 Meeting Minutes.
3. Review of protocols:
  - 1) IBC-2025-260 Renewal
  - 2) IBC-2025-261 Original
  - 3) IBC-2025-265 Original
4. Other Business

#### Principal Discussion

- Quorum confirmed.
- Meeting called to order at 10:31am
- Welcome from the Chair
- Review and approval of July 24, 2025 meeting summary. Approved as written.

#### Review of IBC Registration

1. IBC-2025-260 Renewal  
 General Project Description: This proposal is to analyze properties (e.g., drug susceptibility, antigenicity) of reverse genetically (RG) engineered influenza A and B viruses generated by other groups within VSDB or outside of CDC. Received RG viruses will contain the entire genomes of donor strains used for vaccine production

(example, A/Puerto Rico/8/34 (H1N1)) or vaccine/reference viruses. In addition, their genome may contain mutation(s) identified via surveillance. Reassortant RG viruses containing HA and/or NA genes from other influenza viruses will also be tested. The Molecular Epidemiology Team (MET) will propagate and test RG viruses and prepare stocks needed to raise ferret antisera for antigenic analysis.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-C, III-D-3, III-D-4-a, III-D-7b

Required biological containment level for the work to be implemented: BSL-2, BSL-2E

General points discussed:

- Section 1.1:
  - Please swap Section 1.1 with Section 1.2.

Committee Action: Approve with changes.

## 2. IBC-2025-261 Original

General Project Description: Recombinant Influenza A/Puerto Rico/08/1934 (PR8) H1N1 (BSL-2) viruses will be used for immunological studies related to influenza A virus infection.

Approximate percentage of the viral genome used: N/A

Applicable Sec of NIH Guidelines: III-D-3-a, III-D-7-a

Required biological containment level for the work to be implemented: BSL-2.

General points discussed:

- Section 3.2
  - Please list viruses in terms of microorganisms that will be used in the study instead of cell lines.

Committee Action: Approve with changes.

## 3. IBC-2025-265 Original

General Project Description: The purpose of the study is to construct a series of dual rabies and contraceptive recombinant viruses. We only propose the in vitro studies, and no animal work will be involved in the protocol.

Approximate percentage of the viral genome used: >2/3

Applicable Sec of NIH Guidelines: III-D-1-a, III-D-2-a, III-D-3-a

Required biological containment level for the work to be implemented: BSL-2.

General points discussed:

- Section 2.6:
  - Please include the microorganism here, i.e., list the organism from which GnRH or CKP10 sequence is originally derived.

Committee Action: Approved with changes.

## Other Business

- The MS Form is still open for IBC Charter update volunteers
- The Charter development volunteers will receive meeting series from IBC mailbox
- NIH memorandum
  - NIH memorandum requires CDC to publish the IBC Meeting minutes starting from June, 2025.
  - OLSR created an internal memo for CDC to redact IBC meeting minutes without PII information from the meeting minutes.
  - OLSR is coordinating with OGC, FDA, CDC, and NIH to approve the motion to remove PII.
  - Internal memo is currently reviewed by OLSR Director for an approval and then will route to OGC for final approval.
  - After the approval, all the redacted IBC meeting minutes will be posted on the CDC internet.

- NIH Roaster
  - CDC IBC roster will be removed from the NIH website.
  - IBC mailbox will be used for correspondence with NIH.
- IBC and IACUC collaboration
  - IACUC
    - Updates their IACUC Form to require PIs to specify applicable IBC registration number(s) and animal species
    - Designates the Administrators as IBC-IACUC Liaisons to confirm that animal-related details, such as registration/protocol numbers, animal species etc, are included on both IACUC and IBC forms.
  - IBC:
    - Updates PULSE to grant access to the IBC-IACUC Liaisons and automatically notify the IBC-IACUC Liaison when an animal-related IBC registration is submitted.
    - Revises the Charter to clarify membership roles, including IBC vets, IBC-IACUC Liaison etc.
    - Updates the IBC PULSE form to require the PI to list all other IBC registrations covered under the same IACUC protocol in which the PI is a participant. This information is for administrative purpose only and is not intended for IBC to review beyond the specific registration submitted.
- Meeting adjourned at 11:50 am

Reynolds M  
Salerno -S

Digitally signed by  
Reynolds M. Salerno -S  
Date: 2026.01.06  
16:25:48 -05'00'

---

Reynolds M Salerno, PhD  
Director, Office of Laboratory Systems and Response